{"id":"liposomal-amphotericin-b","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nephrotoxicity (elevated creatinine)"},{"rate":"20-40","effect":"Infusion-related reactions (fever, chills, rigors)"},{"rate":"15-25","effect":"Hypokalemia"},{"rate":"10-20","effect":"Anemia"},{"rate":"10-15","effect":"Hypomagnesemia"}]},"_chembl":{"chemblId":"CHEMBL267345","moleculeType":"Small molecule","molecularWeight":"924.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amphotericin B is a polyene antibiotic that intercalates into ergosterol, a key sterol in fungal cell membranes, forming ion channels that lead to leakage of cellular contents and cell lysis. The liposomal formulation encapsulates the drug in lipid vesicles, which reduces systemic toxicity by preferentially delivering amphotericin B to infected tissues while minimizing exposure to human cell membranes that contain cholesterol rather than ergosterol.","oneSentence":"Liposomal amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause fungal cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:26.591Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive fungal infections (aspergillosis, candidiasis, cryptococcosis)"},{"name":"Empiric therapy for presumed fungal infections in febrile neutropenic patients"},{"name":"Leishmaniasis"}]},"trialDetails":[{"nctId":"NCT06983665","phase":"NA","title":"Human Bioequivalence Study of Liposomal Amphotericin B for Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-05-25","conditions":"Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis","enrollment":42},{"nctId":"NCT07463040","phase":"PHASE3","title":"Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2027-01-01","conditions":"Cutaneous Leihmaniasis","enrollment":900},{"nctId":"NCT00467883","phase":"PHASE2","title":"Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-06","conditions":"Zygomycosis","enrollment":40},{"nctId":"NCT07261150","phase":"PHASE3","title":"Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-05-01","conditions":"Histoplasmosis","enrollment":664},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT07357038","phase":"","title":"A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-30","conditions":"Fungal Disease","enrollment":38},{"nctId":"NCT07337720","phase":"NA","title":"Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-12-20","conditions":"Aspergillosis Invasive","enrollment":40},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT05101187","phase":"PHASE3","title":"Olorofim Aspergillus Infection Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"F2G Biotech GmbH","startDate":"2022-03-31","conditions":"Invasive Aspergillosis","enrollment":225},{"nctId":"NCT05593666","phase":"PHASE2","title":"A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Drugs for Neglected Diseases","startDate":"2022-12-27","conditions":"Primary Visceral Leishmaniasis","enrollment":101},{"nctId":"NCT06525389","phase":"PHASE3","title":"Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-04-01","conditions":"Talaromycosis","enrollment":428},{"nctId":"NCT06977490","phase":"NA","title":"Human Bioequivalence Study of Amphotericin B Liposome for Injection","status":"COMPLETED","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-05-13","conditions":"Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis","enrollment":42},{"nctId":"NCT07191756","phase":"","title":"Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qiu Ye","startDate":"2025-05-15","conditions":"Mucormycosis","enrollment":150},{"nctId":"NCT07185503","phase":"","title":"Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-25","conditions":"Mucormycosis in Hematologic Malignancies","enrollment":60},{"nctId":"NCT06414512","phase":"PHASE2","title":"Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2024-04-09","conditions":"Cryptococcal Meningitis","enrollment":48},{"nctId":"NCT07135778","phase":"","title":"Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-19","conditions":"Invasive Fungal Disease","enrollment":36},{"nctId":"NCT04157465","phase":"NA","title":"Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-11-07","conditions":"Antifungal Agents, Invasive Fungal Infections, Mycoses","enrollment":216},{"nctId":"NCT06980493","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sohag University","startDate":"2025-04-01","conditions":"Tinea Capitis","enrollment":30},{"nctId":"NCT06640296","phase":"","title":"L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis","status":"ENROLLING_BY_INVITATION","sponsor":"Istituto Giannina Gaslini","startDate":"2023-12-12","conditions":"Invasive Fungal Infections, Prophylaxis, Invasive Fungal Disease","enrollment":120},{"nctId":"NCT06926569","phase":"NA","title":"Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2025-05-01","conditions":"HIV/AIDS-associated Talaromycosis","enrollment":116},{"nctId":"NCT04059770","phase":"PHASE2","title":"Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients","status":"COMPLETED","sponsor":"Alessandro Pasqualotto","startDate":"2020-02-14","conditions":"Histoplasmosis, AIDS","enrollment":118},{"nctId":"NCT03656081","phase":"PHASE3","title":"Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2018-12-19","conditions":"Chronic Pulmonary Aspergillosis","enrollment":224},{"nctId":"NCT05814432","phase":"PHASE3","title":"Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS","status":"RECRUITING","sponsor":"Federal University of Health Science of Porto Alegre","startDate":"2025-01-16","conditions":"Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression","enrollment":279},{"nctId":"NCT06756191","phase":"PHASE4","title":"Antifungal Drugs in Pulmonary Mucormycosis","status":"NOT_YET_RECRUITING","sponsor":"Bin Cao","startDate":"2025-01-10","conditions":"Pulmonary Mucormycosis","enrollment":312},{"nctId":"NCT01058174","phase":"PHASE3","title":"Liver Transplant European Study Into the Prevention of Fungal Infection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12-15","conditions":"Liver Transplantation, Mycoses","enrollment":350},{"nctId":"NCT06123832","phase":"","title":"Study of the Clinical Benefits of Different Formulations of Amphotericin B","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-09-01","conditions":"Efficacy, Safety","enrollment":184},{"nctId":"NCT05468372","phase":"PHASE2","title":"Amphotericin Versus Posaconazole for Pulmonary Mucormycosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-07-01","conditions":"Mucormycosis; Pulmonary (Etiology)","enrollment":50},{"nctId":"NCT06495905","phase":"NA","title":"Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-07-30","conditions":"Pulmonary Mucormycosis","enrollment":30},{"nctId":"NCT03529617","phase":"","title":"Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-10-19","conditions":"Pharmacokinetics, Liposomal Amphotericin B, Critically Ill Patients","enrollment":60},{"nctId":"NCT06449040","phase":"PHASE1, PHASE2","title":"Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly","status":"COMPLETED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2019-03-01","conditions":"Cutaneous Leishmaniasis, American","enrollment":28},{"nctId":"NCT04799236","phase":"PHASE3","title":"Treatment of Mucosal Bolivian Leishmaniasis","status":"RECRUITING","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2021-04-01","conditions":"Mucosal Leishmaniasis","enrollment":120},{"nctId":"NCT04502381","phase":"PHASE2","title":"Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-07-01","conditions":"Pulmonary Mucormycosis","enrollment":30},{"nctId":"NCT00419770","phase":"PHASE2","title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2007-10","conditions":"Mucormycosis","enrollment":20},{"nctId":"NCT05913921","phase":"PHASE1","title":"Bioequivalence of Amphotericin B Liposome for Injection","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-06-02","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT06040489","phase":"PHASE2, PHASE3","title":"Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly","status":"RECRUITING","sponsor":"University of Brasilia","startDate":"2022-06-22","conditions":"Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous","enrollment":100},{"nctId":"NCT04267497","phase":"PHASE1","title":"Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2019-10-18","conditions":"Invasive Pulmonary Aspergillosis","enrollment":13},{"nctId":"NCT03945448","phase":"PHASE2, PHASE3","title":"Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","status":"RECRUITING","sponsor":"Makerere University","startDate":"2019-06-20","conditions":"Cryptococcal Meningitis","enrollment":356},{"nctId":"NCT05749380","phase":"PHASE1","title":"Pharmacokinetics and Safety of AmBisome and DKF-5122","status":"COMPLETED","sponsor":"Dongkook Pharmaceutical Co., Ltd.","startDate":"2020-09-07","conditions":"Invasive Fungal Infections, Neutropenic Fever","enrollment":38},{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT02656797","phase":"PHASE2","title":"Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2018-01-30","conditions":"Leishmaniasis","enrollment":13},{"nctId":"NCT05108545","phase":"PHASE3","title":"A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-12-15","conditions":"Neutropenia and Fever","enrollment":93},{"nctId":"NCT00885703","phase":"PHASE1, PHASE2","title":"High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-04-16","conditions":"Cryptococcal Meningitis, HIV Infections","enrollment":168},{"nctId":"NCT04993222","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2020-06-04","conditions":"Bioequivalence","enrollment":12},{"nctId":"NCT02320604","phase":"PHASE4","title":"Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-03-22","conditions":"Morbid Obesity","enrollment":16},{"nctId":"NCT02273661","phase":"PHASE2","title":"Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-11-19","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":174},{"nctId":"NCT03399955","phase":"PHASE2","title":"Short Course Regimens for Treatment of PKDL (Sudan)","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2018-05-09","conditions":"PKDL - Post-Kala-Azar Dermal Leishmanioid","enrollment":110},{"nctId":"NCT03636659","phase":"PHASE1","title":"Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition","status":"COMPLETED","sponsor":"Aurobindo Pharma Ltd","startDate":"2018-05-02","conditions":"Visceral Leishmaniasis","enrollment":140},{"nctId":"NCT02011958","phase":"PHASE3","title":"Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2014-07","conditions":"Visceral Leishmaniasis","enrollment":59},{"nctId":"NCT03327727","phase":"PHASE2","title":"VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults","status":"TERMINATED","sponsor":"Vical","startDate":"2018-02-20","conditions":"Invasive Aspergillosis, Invasive Pulmonary Aspergillosis","enrollment":4},{"nctId":"NCT00361517","phase":"PHASE3","title":"To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-06-01","conditions":"Aspergillosis","enrollment":47},{"nctId":"NCT03511820","phase":"","title":"A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2016-05-24","conditions":"Neutropenia, Febrile","enrollment":54},{"nctId":"NCT01615809","phase":"PHASE2","title":"Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2011-10","conditions":"Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia, Myeloblastic Leukaemia","enrollment":32},{"nctId":"NCT03311607","phase":"PHASE4","title":"Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2014-04-08","conditions":"Post-kala-azar Dermal Leishmaniasis","enrollment":280},{"nctId":"NCT00936910","phase":"PHASE4","title":"Antifungal Locks to Treat Fungal-related Central Line Infections","status":"COMPLETED","sponsor":"Bill McGhee","startDate":"2006-09","conditions":"Central Line Fungal Infections","enrollment":13},{"nctId":"NCT01310738","phase":"PHASE4","title":"Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil","status":"TERMINATED","sponsor":"University of Brasilia","startDate":"2011-02","conditions":"Visceral Leishmaniasis","enrollment":378},{"nctId":"NCT01067443","phase":"PHASE2","title":"Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2010-03","conditions":"Primary Visceral Leishmaniasis","enrollment":151},{"nctId":"NCT00082537","phase":"PHASE2","title":"MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Neutropenia, Fever","enrollment":100},{"nctId":"NCT01501708","phase":"PHASE2","title":"Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-12","conditions":"Leukemia, Transplantation, Hematopoietic Stem Cell","enrollment":55},{"nctId":"NCT02686853","phase":"PHASE4","title":"Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"Hui Bu","startDate":"2016-01","conditions":"Cryptococcal Meningitis","enrollment":40},{"nctId":"NCT00832208","phase":"PHASE2","title":"Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL","status":"TERMINATED","sponsor":"Drugs for Neglected Diseases","startDate":"2009-04","conditions":"Visceral Leishmaniasis","enrollment":124},{"nctId":"NCT01122771","phase":"PHASE3","title":"Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2010-05","conditions":"Visceral Leishmaniasis","enrollment":602},{"nctId":"NCT02527928","phase":"","title":"Cost-Effectiveness of Amphotericin B","status":"UNKNOWN","sponsor":"Hospital Universitario Evangelico de Curitiba","startDate":"2015-09","conditions":"Invasive Fungal Infections","enrollment":200},{"nctId":"NCT00362544","phase":"PHASE4","title":"PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-10","conditions":"Leukemia","enrollment":30},{"nctId":"NCT00334412","phase":"PHASE4","title":"COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-03","conditions":"Invasive Aspergillosis","enrollment":30},{"nctId":"NCT01259713","phase":"PHASE3","title":"Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-04","conditions":"Invasive Fungal Disease","enrollment":355},{"nctId":"NCT00106288","phase":"PHASE3","title":"Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-01","conditions":"Candidiasis","enrollment":637},{"nctId":"NCT00047827","phase":"PHASE2","title":"Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Aspergillosis","enrollment":2},{"nctId":"NCT01303549","phase":"PHASE4","title":"Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-11","conditions":"Liver Disease, Fungal Infection","enrollment":61},{"nctId":"NCT02136030","phase":"NA","title":"Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"TTY Biopharm","startDate":"2011-02","conditions":"Cryptococcal Meningitis","enrollment":84},{"nctId":"NCT01566552","phase":"PHASE4","title":"Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis","status":"UNKNOWN","sponsor":"Banaras Hindu University","startDate":"2014-06","conditions":"Visceral Leishmaniasis","enrollment":1300},{"nctId":"NCT02025491","phase":"PHASE3","title":"Liposomal Amphotericin in Disseminated Leishmaniasis","status":"COMPLETED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2011-04","conditions":"Disseminated Leishmaniasis","enrollment":20},{"nctId":"NCT00451711","phase":"PHASE2","title":"Intermittent Liposomal Amphotericin B Primary Prophylaxis","status":"UNKNOWN","sponsor":"Bayside Health","startDate":"2007-05","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT00003315","phase":"PHASE3","title":"Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1997-07","conditions":"Infection","enrollment":200},{"nctId":"NCT01652859","phase":"PHASE1","title":"An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2012-02","conditions":"Normal Healthy Subjects","enrollment":36},{"nctId":"NCT01437020","phase":"PHASE1, PHASE2","title":"SCH708980 With and Without AmBisome for Visceral Leishmaniasis","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Leishmaniasis, Effects of Immunotherapy","enrollment":""},{"nctId":"NCT00008359","phase":"PHASE3","title":"Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":"Cancer","enrollment":""},{"nctId":"NCT00491426","phase":"","title":"Antimicrobial PK in Infants With Suspected or Confirmed Infection","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-01","conditions":"Infection","enrollment":450},{"nctId":"NCT00003938","phase":"PHASE3","title":"Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1999-06","conditions":"Cancer","enrollment":115},{"nctId":"NCT00418951","phase":"PHASE2","title":"Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-11","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT01254708","phase":"PHASE2","title":"Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients","status":"SUSPENDED","sponsor":"University Health Network, Toronto","startDate":"2012-01","conditions":"Lung Transplant Recipient","enrollment":4},{"nctId":"NCT00371995","phase":"PHASE2","title":"Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2007-10","conditions":"Visceral Leishmaniasis","enrollment":150},{"nctId":"NCT00876824","phase":"PHASE3","title":"To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar","status":"COMPLETED","sponsor":"Bharat Serums and Vaccines Limited","startDate":"2009-07","conditions":"Leishmaniasis, Visceral","enrollment":500},{"nctId":"NCT00421187","phase":"PHASE4","title":"Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2007-03","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT00001107","phase":"PHASE4","title":"Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Candidiasis","enrollment":500},{"nctId":"NCT00523965","phase":"PHASE3","title":"Combination Therapy in Indian Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2007-09","conditions":"Leishmaniasis, Visceral","enrollment":624},{"nctId":"NCT00326157","phase":"PHASE2","title":"PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-06","conditions":"Fungus Diseases","enrollment":34},{"nctId":"NCT00696969","phase":"PHASE3","title":"Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2008-06","conditions":"Visceral Leishmaniasis","enrollment":634},{"nctId":"NCT01040156","phase":"","title":"Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","startDate":"2008-08","conditions":"Systemic Aspergillosis, Systemic Candidiasis","enrollment":""},{"nctId":"NCT00391014","phase":"PHASE2","title":"Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-01","conditions":"Acute Myeloid Leukemia, Allogeneic Haematopoietic Progenitor Cell Transplant","enrollment":150},{"nctId":"NCT00628719","phase":"PHASE3","title":"Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2008-02","conditions":"Visceral Leishmaniasis","enrollment":400},{"nctId":"NCT00670657","phase":"PHASE4","title":"CRITIC - Treatment of Candidemia and Invasive Candidiasis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-05","conditions":"Candidemia, Invasive Candidiasis","enrollment":39},{"nctId":"NCT00177710","phase":"PHASE3","title":"Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-01","conditions":"Lung Transplantation, Fungal Infections","enrollment":48},{"nctId":"NCT00037206","phase":"PHASE2, PHASE3","title":"A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-05","conditions":"Aspergillosis","enrollment":30},{"nctId":"NCT00370825","phase":"PHASE2","title":"Combination Chemotherapy for the Treatment of Indian Kala-Azar","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2006-09","conditions":"Visceral Leishmaniasis","enrollment":200},{"nctId":"NCT00161356","phase":"PHASE4","title":"Ambisome in Liver Transplant Patients","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2005-09","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT00697944","phase":"PHASE4","title":"Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients","status":"UNKNOWN","sponsor":"Fovea","startDate":"2008-03","conditions":"Sepsis, Candida","enrollment":30},{"nctId":"NCT00148148","phase":"PHASE2","title":"A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2004-05","conditions":"Hematopoietic Stem Cell Transplantation, Fungus Diseases","enrollment":75},{"nctId":"NCT00386997","phase":"PHASE4","title":"ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2006-11","conditions":"Fungal Infection","enrollment":20},{"nctId":"NCT00263315","phase":"PHASE2, PHASE3","title":"Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2000-01","conditions":"Aspergillosis","enrollment":320},{"nctId":"NCT00158730","phase":"PHASE3","title":"Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-04","conditions":"Invasive Aspergillosis, Other Fungal Infections","enrollment":800}],"_emaApprovals":[],"_faersSignals":[{"count":49,"reaction":"DRUG INEFFECTIVE"},{"count":19,"reaction":"RESPIRATORY FAILURE"},{"count":16,"reaction":"ACUTE KIDNEY INJURY"},{"count":16,"reaction":"DRUG INTERACTION"},{"count":14,"reaction":"PNEUMONIA"},{"count":13,"reaction":"ASPERGILLUS INFECTION"},{"count":13,"reaction":"MULTIPLE ORGAN DYSFUNCTION SYNDROME"},{"count":11,"reaction":"BRONCHOPULMONARY ASPERGILLOSIS"},{"count":10,"reaction":"CONDITION AGGRAVATED"},{"count":10,"reaction":"DRUG LEVEL INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AmBisome","Ambisome","high dosage","Lipo-AB","LAMB"],"phase":"marketed","status":"active","brandName":"Liposomal Amphotericin B","genericName":"Liposomal Amphotericin B","companyName":"Taiwan Liposome Company","companyId":"taiwan-liposome-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liposomal amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause fungal cell death. Used for Invasive fungal infections (aspergillosis, candidiasis, cryptococcosis), Empiric therapy for presumed fungal infections in febrile neutropenic patients, Leishmaniasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}